Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.

Seidl-Philipp M, Schratter H, Auer J, Schwantzer G, Lammer M, Hinteregger P, Vergeiner I, Gruber R, Wolf P, Hofer A

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG6 Mar 2026Cited by 1 (Europe PMC)

PMID41793078DOI10.1111/ddg.15996PepBankPUB-41793078

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In Austrian adults with erythropoietic protoporphyria, the median EPP quality of life score rose from 11.11 before treatment to 79.17 on afamelanotide.
In plain wordsIn Austrian adults with EPP, quality of life scores were much higher on afamelanotide than before treatment.
Peptide
Melanotan I (afamelanotide)
Outcome
IncreaseEPP quality of life score
Study
n = 20
Comparator
Baseline (before treatment)
Outcome group
Quality of life · Skin and wound
Studied dose
Dose not stated
Measurements
EPP QoL score median
11.11 points
before treatment
EPP QoL score median
79.17 points
on afamelanotide
Source sentences
Summary
Before treatment, the EPP QoL score had a median of 11.11 (IQR 3.03-19.44) and increased to a median of 79.17 (IQR 75.00-97.22) under therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from all Austrian EPP patients treated with afamelanotide in 2023 (n = 20) were analyzed and compared to baseline data on quality of life, phototoxic burn tolerance time (PBTT), reported UV index on the day with the longest PBTT, and incidence and severity of phototoxic reactions.
Report a problemFND-4179307801
02HumanObservational studyEfficacy outcome
In Austrian adults with erythropoietic protoporphyria, median phototoxic burn tolerance time rose from 15 to 250 minutes on afamelanotide.
In plain wordsIn Austrian adults with EPP, people tolerated light for much longer on afamelanotide than before treatment.
Peptide
Melanotan I (afamelanotide)
Outcome
IncreasePhototoxic burn tolerance time
Study
n = 20
Comparator
Baseline (before treatment)
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated
Measurements
PBTT median
15 minutes
before treatment
PBTT median
250 minutes
on afamelanotide
Source sentences
Summary
Phototoxic burn tolerance time (PBTT) increased from a median of 15 minutes (IQR 10-25) to a median of 250 minutes (IQR 120-300) under therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from all Austrian EPP patients treated with afamelanotide in 2023 (n = 20) were analyzed and compared to baseline data on quality of life, phototoxic burn tolerance time (PBTT), reported UV index on the day with the longest PBTT, and incidence and severity of phototoxic reactions.
Report a problemFND-4179307802
03HumanObservational studyEfficacy outcome
In Austrian adults with erythropoietic protoporphyria, the share of patients with phototoxic reactions fell from 88% before therapy to 33% on afamelanotide.
In plain wordsIn Austrian adults with EPP, fewer people had light reactions on afamelanotide than before treatment.
Peptide
Melanotan I (afamelanotide)
Outcome
DecreasePatients with phototoxic reactions
Study
n = 20
Comparator
Baseline (before treatment)
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated
Measurements
Patients with phototoxic reactions
88%
before therapy
Patients with phototoxic reactions
33%
on therapy
Source sentences
Summary
Before therapy 88% of patients had phototoxic reactions, while on therapy only 33% were affected.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from all Austrian EPP patients treated with afamelanotide in 2023 (n = 20) were analyzed and compared to baseline data on quality of life, phototoxic burn tolerance time (PBTT), reported UV index on the day with the longest PBTT, and incidence and severity of phototoxic reactions.
Report a problemFND-4179307803
04HumanObservational studySafety outcome
In Austrian adults with erythropoietic protoporphyria, afamelanotide side effects were only mild and transient.
In plain wordsIn Austrian adults with EPP, side effects of afamelanotide were mild and short-lived.
Peptide
Melanotan I (afamelanotide)
Outcome
Not applicableTreatment side effects
Study
n = 20
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Treatment side effects were only mild and transient.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from all Austrian EPP patients treated with afamelanotide in 2023 (n = 20) were analyzed and compared to baseline data on quality of life, phototoxic burn tolerance time (PBTT), reported UV index on the day with the longest PBTT, and incidence and severity of phototoxic reactions.
Report a problemFND-4179307804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.